UnknownNot Applicable

Neonatal Cord Blood Screening for HDN

400 participantsStarted 2022-12-01

Plain-language summary

To evaluate the diagnostic efficiency of antibodies screening in cord blood for detection of HDN. To help finding the antigen negative blood in a timely manner and reduce the morbidities and mortalities of HDN

Who can participate

Age range1 Day – 3 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Full term neonates \>/= 37 weeks. * ABO blood compatible mother and neonate Exclusion Criteria: * Preterm neonates \< 37 weeks. * ABO incompatibility between mother and neonate

What they're measuring

evaluate the diagnostic efficiency of antibodies screening in cord blood for detection of HDN

Timeframe: Baseline

Trial details

NCT IDNCT05617612

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-01

Contact for this trial

Shimaa AE Ahmed, MD

01065952778 shimaaabdalaleem@gmail.com

View on ClinicalTrials.gov More HDN - Hemolytic Disease of the Newborn trials